| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7731986 | PROVENSIS | Therapeutic foam |
Nov, 2024
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6846412 | PROVENSIS | Combination filter assembly |
Jul, 2022
(1 year, 2 months ago) | |
| US8122917 | PROVENSIS | Apparatus and method for dispensing foam |
Sep, 2024
(11 months from now) | |
| US7814943 | PROVENSIS | Apparatus and method for dispensing foam |
Nov, 2027
(4 years from now) | |
| US9480652 | PROVENSIS | Aerosol valve |
May, 2032
(8 years from now) | |
Varithena is owned by Provensis.
Varithena contains Polidocanol.
Varithena has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Varithena are:
- US6846412
Varithena was authorised for market use on 25 November, 2013.
Varithena is available in solution;intravenous dosage forms.
Varithena can be used as a method of generating an injectable foam of controlled density and bubble size, a method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities.
The generics of Varithena are possible to be released after 12 May, 2032.
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 25 November, 2013
Treatment: A method of generating an injectable foam of controlled density and bubble size; A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the ta...
Dosage: SOLUTION;INTRAVENOUS
VARITHENA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic